As the immune response develops, an increasing proportion of the cells produced by clonal expansion differentiate into effector cells. The B cells become plasma cells and synthesize and secrete specific antibody (predominantly as IgM, IgG or IgA) which can participate in various forms of reaction, such as precipitation of antigen, killing of target cells (usually involving complement), stimulation of phagocytosis by granulocytes or macro phages, or induction of tissue inflammation. The effector T cells may be cytotoxic for target cells, but their main response on exposure to antigen is the synthesis and release of a wide range of lymphokines that modify the behaviour of macrophages and other connective tissue cells to produce the complicated changes of chronic inflammation.
Effects of glucocorticoids on the immune response
Glucocorticoids induce a lymphopenia with selective depletion of T cells from the circulating blood (Haynes & Fauci 1978) : many of these cells appear to be sequestered in the bone marrow (Fauci 1975) but not in the spleen, since previous splenectomy does not influence the process (Beardsley & Cohen 1978) . The explanation for the modification of lymphocyte recirculation by glucocorticoids is not yet clear; pharmacological concentrations reduce 
lymphocyte responses in chemotactic tests (Beer & Center 1980 ), but it is not known whether glucocorticoids affect cellular progress through post-capillary venule or movement through the lymph nodes. Nevertheless, it is now recognized that interference with T-cell recirculation diminishes the probability of lymphocyte: antigen interaction and so is an important component of the immunosuppressive action of glucocorticoids in man.
Glucocorticoids have a relatively limited capacity to reduce an established immune response, and cell-mediated reactions are more susceptible than antibody formation. Moreover, these agents are much more potent if administered at, or just before, the time of first exposure to antigen when both cell-mediated reactions and humoral antibody formation can be suppressed almost completely (Craddock 1978) .
Most of the human experimental work on the mode of action of glucocorticoids as immunosuppressives has been performed on lymphocytes isolated from the peripheral blood, since they are easily accessible for repeated testing. Most of the studies have examined the effect of glucocorticoids on lymphocyte growth (as a measure of clonal expansion) in preference to the study of differentiation. Moreover, purified antigens have been used in a minority of the studies and the usual approach has been to assess proliferation induced by purified plant proteins (mitogens) which stimulate large subpopulations: this artificial stimulus has been used because the response can be measured much more easily and precisely.
There is strong evidence (summarized by Cupps & Fauci 1982 ) that glucocorticoids administered in vivo or in vitro depress the response of peripheral blood lymphocytes to various forms of stimulation (mitogen, mixed lymphocyte reaction and antigen): the slowing of cell proliferation would interfere with the immune response and must be an important component of glucocorticoid-induced immunosuppression. Glucocorticoids block the production of II I and II 2, but neither the generation of II 2 receptors on the stimulated cells (Gillis et al. 1979a ,b, Larsson 1980 ) nor the intrinsic lymphocyte growth mechanisms are affected. T cells appear to be more sensitive than B cells to suppression of in vitro growth by glucocorticoids (Blomgren & Andersson 1976), but it is possible that this may reflect the relative sensitivities of the different Iymphokines and monokines. Evidence that the accessory cells may be the major target for glucocorticoids is provided by the observation that lymphocytes in culture are more sensitive to glucocorticoids during the initial period in culture when interleukins are being generated, than at later periods when the accessory cells have a more subservient role (Ramer & Yu 1978 , Neifeld & Tormey 1979 . Experimental studies of the action of glucocorticoids on suppressor cells are conflicting with reports of abrogation (Haynes & Fauci 1979 ) and of augmentation (Hirschberg et al. 1980 ) of various forms of concanavalin A-induced suppressor cell function. Since relatively little is known of the mechanisms of induction of differentiation into plasma cells, it is hardly surprising that the mechanism by which glucocorticoids suppress antibody production has not yet been explained, but it is currently thought that again the effect is mediated through the accessory cells, as well as by direct action on the B-cells (Cupps & Fauci 1982) . It is abundantly clear that glucocorticoids do not have a single action on the immune response, and that these drugs interfere with several interacting processes to cause particularly powerful suppression of the early response~o antigens.
Cellular basis of glucocorticoid hormone action During the last decade there have been important advances in clarifying the mode of action of glucocorticoid hormones at the cellular level (Chan & O'Malley 1978 , Baxter & Funder 1979 . It now appears that these hormones act in a similar manner on all cell types. The processes are summarized in Figure 4 :
(1) After diffusion through the cell membrane into the cytoplasm, the glucocorticoid binds to cytoplasmic receptors.
(2) The glucocorticoid-receptor complex translocates into the cell nucleus; this process has recently been visualized (Papamichail et al. 1980 ). Figure 4 . Mechanism of action of glucocorticoids (3) These complexes are then bound by additional nuclear receptors, modifying transcription of mRNA; the precise part of the genome affected depends upon the differentiation of the particular target cell.
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(4) This is followed by an altered pattern of protein synthesis and so the cell changes function; this is the ultimate glucocorticoid effect. Early studies have indicated that cells with abundant cytosol glucocorticoid receptors are sensitive to glucocorticoids, and that insensitive cells generally have many fewer receptors (Lippman 1973) : however, certain lymphoblastoid cell lines with abundant receptors were almost totally refractory to the drugs (Gailani et al. 1973 , Lippman et al. 1974 . Moreover, recent work has shown that Til and Ti' cells isolated from normal peripheral blood, despite having markedly different sensitivity to glucocorticoids, have a remarkably similar content of receptors (Fauci et al. 1980) .
Human responsiveness to glucocorticoids
In clinical practice, individual patients may vary greatly in their response to similar therapeutic doses of glucocorticoids. This variation may be ascribed in part to the nature, extent and severity of the underlying disease and to variations in absorption and elimination of the glucocorticoids. In addition, there is also likely to be an inherent variability in patient sensitivity to immunosuppression by glucocorticoids. There is some individual variation in the number of glucocorticoid receptors in lymphocytes (Crabtree et al. 1979) ; however, there have been few attempts in non-malignant conditions to determine whether such differences correlate well with immune reactivity, probably because unacceptably large blood samples are required for the assay of receptor numbers. Robertson et al. (1981) developed a simple assay to determine the responsiveness of peripheral blood mononuclear cells to growth inhibition by glucocorticoids. This assay uses a relatively small volume of venous blood (10--20 ml) and measures the effect of glucocorticoids on cell growth during the first day of culture when the responding cells are entering the first G I-phase. The assay gives reproducible results, and a log-linear doseresponse curve can be constructed correlating the concentration of glucocorticoid in the tissue culture fluid with the calculated percentage of cells growing in volume ( Figure 5 ). The sensitivity of the cells from any subject can thus be conveniently described by the slope of Figure 6 . Dose-response curves for two patients at the extreme ends of the observed distribution in a study of normal subjects this response curve, and assays carried out on blood samples removed at intervals over a period of 4-6 months from normal individuals have been shown to give consistent results. In a study of-125 normal subjects, the slope of the log-dose response to hydrocortisone was shown to have an approximately normal distribution. Peripheral blood mononuclear cells from patients with a wide range of diseases (rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica, sarcoidosis, Crohn's disease and ulcerative colitis) also show a similar distribution of slopes of the log-dose response. At the extremes of the population ( Figure 6 ) there are some subjects who have a very flat response so that cell growth is virtually unaffected, even at concentrations far greater than those likely to be achieved by pharmacological doses of glucocorticoids. There is also a small number of subjects whose cells are very sensitive and in whom growth is very seriously curtailed even at moderate concentrations. Most subjects show an intermediate response with some effect becoming obvious at 10-9 mol/I and with only 60-70% cells growing at 10-7 mol/l. . Assuming that lymphocytes in the main lymphoid organs behave in a similar manner to peripheral mononuclear cells, that cells from different individuals behave similarly with regard to the rate of growth and life span, and that similar blood levels of glucocorticoid are attained during the course of treatment, then it is possible to calculate the rate of increase of numbers of stimulated cells for any subject. Figure 7 shows the results of calculations of the effect of reduction in percentage of replicating cells on the build up of cell numbers in a population where the total cell cycle time is one day. Curve A shows the behaviour of cells without growth suppression. Curves Band C show the effect of 20% and 40% suppression of growth fraction: these conditions were selected since they correspond to the extent of growth inhibition encountered at the lower and upper blood concentrations achieved during glucocorticoid therapy in the average subject. Starting from 100 cells, there are 1600 after 4 days growth without suppression, but only 1050 and 655 with 20% and 40% suppression. Thus suppression retards the growth in cell numbers and the effect becomes greater the longer it lasts. When the same dose of glucocorticoid is given, a responsive subject (such as subject L in Figure 6 ) will, within a few days, show a marked reduction in the number of new lymphocytes available to enter the circulation, compared with an unresponsive subject (such as subject K in Figure 6 ). This may be the way in which glucocorticoids exert their main immunosuppressive action.
The possibility of employing this in vitro test to predict the likely clinical response of individual patients to glucocorticoid therapy is currently being evaluated in our laboratories. Preliminary studies suggest that a steep dose-response curve is associated with a good response to treatment, but many more patients must be studied prospectively before any claims can be made for the test as a prognostic indicator. In subjects showing little or no inhibition of lymphocyte growth by glucocorticoids in vitro, it would seem logical to employ alternative therapy if immunosuppression is required.
Conclusion
Glucocorticoids, because of their different actions in laboratory animals and man, have proved to be difficult drugs to study and, as yet, their exact mode of action in suppressing the immune response is not fully understood, although some aspects have now been elucidated as a result of recent in vitro studies. Despite our lack of understanding of the mede of action of glucocorticoids these drugs remain valuable therapeutic agents, but unwanted and sometimes damaging side effects affecting mineral, carbohydrate, protein and fat metabolism have restricted their use in clinical practice. It is to be hoped that the identification of patients who are unlikely to benefit from glucocorticoid immunosuppressive therapy will prevent these patients being given large doses of glucocorticoids, with the consequent development of iatrogenic disease: there would then be less inhibition in the prescription of glucocorticoids for those patients who are most likely to benefit from their administration.
